↓ Skip to main content

Therapeutic potential of human embryonic stem cell transplantation in patients with cerebral palsy

Overview of attention for article published in Journal of Translational Medicine, December 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs
2 blogs
twitter
2 tweeters

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic potential of human embryonic stem cell transplantation in patients with cerebral palsy
Published in
Journal of Translational Medicine, December 2014
DOI 10.1186/s12967-014-0318-7
Pubmed ID
Authors

Geeta Shroff, Anupama Gupta, Jitender Kumar Barthakur

Abstract

BackgroundThe present study evaluated the efficacy and safety of human embryonic stem cell (hESC) therapy in patients with CP.Materials and methodsThis analysis included patients (30 days-18 yr) with documented diagnosis of CP. The study consisted of four treatment phases (T1, T2, T3, T4) separated by gap phases. Efficacy of hESC therapy was evaluated based on Gross Motor Function Classification Scores Expanded and Revised (GMFCS- E & R; 1-good to 5-bad).ResultsNinety one patients were included and all received hESC therapy in T1, 66 patients returned for T2, 38 patients for T3, and 15 patients for T4. Overall, 30.2% patients achieved GMFCS- E & R score 1 during the study with different number of patients achieving GMFCS score 1 by the end of each treatment phase (T1: 6 [6.6%]; T2: 7 [10.6%]; T3: 11 [28.9%]; and T4: 5 [33.3%]). All patients in up to 2 yr (n¿=¿10), 2-4 yr (n¿=¿10), 4-6 yr (n¿=¿9), and 6-12 yr (n¿=¿8) age groups except one of the 5 patients in the age group of 12-18 yr transitioned from GMFCS-E & R score 5 to lower scores by end of T1. Most patients transitioned to GMFCS-E & R score 2 (n¿=¿34) from higher scores by end of T2. Eleven patients achieved GMFCS-E & R score 1 by end of T3. No serious adverse events were observed.ConclusionUse of hESC therapy in patients with CP is effective and safe. hESC therapy has demonstrated significant improvement in GMFCS-E & R scale.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 41 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 17%
Student > Master 6 14%
Student > Bachelor 6 14%
Student > Ph. D. Student 6 14%
Student > Postgraduate 4 10%
Other 5 12%
Unknown 8 19%
Readers by discipline Count As %
Medicine and Dentistry 12 29%
Neuroscience 3 7%
Nursing and Health Professions 3 7%
Arts and Humanities 2 5%
Agricultural and Biological Sciences 2 5%
Other 10 24%
Unknown 10 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2017.
All research outputs
#2,240,590
of 22,774,233 outputs
Outputs from Journal of Translational Medicine
#361
of 3,984 outputs
Outputs of similar age
#33,100
of 356,557 outputs
Outputs of similar age from Journal of Translational Medicine
#13
of 123 outputs
Altmetric has tracked 22,774,233 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,984 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,557 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.